XCancer

A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping

Description:

Open label, non-randomized, multi-center, within-subject comparative study to evaluate the tolerability and the diagnostic utility of Lymphoseek with optional comparison to VBD in pediatric subjects with melanoma, rhabdomyosarcoma, or other solid tumor. Subject age will range from neonatal through 17 years.

Sponsor:

Unknown Organization

Phase:

Phase 2

Contacts:

Michael Blue, MD (STUDY_DIRECTOR)

Government Study Link:

NCT02509598 - Click here to see study on

ClinicalTrials.gov

tilmanocept

Isotope(s):
Target(s):
  • Mannose Receptor (CD206/MRC1)
Ligand Class: Small Molecules
Inclusion
  • * The subject's parent(s)/legal guardian(s) understand(s) and voluntarily signed an informed consent document prior to any study-related assessments/procedures being conducted. Where locally applicable, the subject also understands and voluntarily provides his/her assent prior to any study-related assessments/procedures being conducted
  • Male subjects of childbearing potential must be willing to use a condom during sexual intercourse and shall not father a child during the course of the study or will practice complete abstinence while on study
  • Subject has been diagnosed with melanoma, rhabdomyosarcoma, or other tumor where tumor resection or biopsy is planned and lymph node mapping is appropriate
  • Age \< 18 years
  • The subject is clinically node negative (cN0) at the time of screening
Exclusion
  • Has a known allergy to dextran or VBD (if intended to be used)
  • Has had previous surgery or radiation to node basins that would be involved in the intraoperative lymph node mapping (ILM) procedure
  • Has a history of alcohol abuse or alcohol dependency in the 3 years before study entry, or is an alcoholic or drug addict, as determined by the investigator
  • Before the administration of Lymphoseek, has received any radiopharmaceutical within 7 radioactive half-lives of that radiopharmaceutical
  • * The subject has had preoperative radiation therapy